CStone Pharma Replaces Chairman Amid Huge Losses, Irregular Investment
CStone’s executive reshuffle comes after company discovers questionable investment made by finance vice president in 2021 Key Takeaways: CStone brought four products to market last year, and its losses have…
RELATED ARTICLES
-
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG -
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK
-
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK 603259.SHG
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
